PERFORMANCE IN DELIVERING CLINICAL RESEARCH – Q4 (2021/22)



REC Number	IRAS Number	Project Title	Target Number of Patients Agreed?	Minimum Number of Patients Agreed	Maximum Number of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason for Closure of Trial
15/NE/0143	174391	GAST 4652	Number Agreed	3	3	Date Agreed	28/04/2021	5	28/04/2021	5	Recruitment Finished
20/SC/0418	282222	COASPIRE (COVID-19 Anti- inflammatory SPecific Immunomodulation and Recovery Enhancing)	Number Agreed	2	2	Date Agreed	31/05/2021	2	30/04/2021	2	Withdrawn By Host
19/LO/1449	269837	Keynote-966	Number Agreed	3	3	Date Agreed	31/05/2021	9	12/05/2021	9	Recruitment Finished
15/NE/0144	179243	GAST 4684	Number Agreed	3	3	Date Agreed	25/05/2016	3	06/06/2021	3	Recruitment Finished
21/NW/0125	294164	COV-COMPARE Immunogenicity of vaccine VLA2001 compared to AZD1222	Number Agreed	160	160	Date Agreed	22/05/2021	94	26/05/2021	109	Recruitment Finished
20/EE/0031	275993	PACIFIC Stroke - 19766 - Non- cardioembolic ischaemic stroke	Number Agreed	1	1	Date Agreed	02/08/2021	1	21/08/2021	1	Recruitment Finished
18/LO/0448	241283	CALDOSE - 1	Number Agreed	2	2	Date Agreed	22/01/2020	2	31/08/2021	2	Recruitment Finished
19/SW/0041	260477	Pembrolizumab + Lenvatinib verses Docetaxel in 2L+ NSCLC (LEAP-008)	Number Agreed	4	4	Date Agreed	28/02/2020	1	15/02/2022	1	Recruitment Finished
21/LO/0193	294285	1366-0005 BI 685509 Diabetic KD	Number Agreed	2	2	Date Agreed	01/03/2022	1	08/03/2022	1	Recruitment Finished
19/NE/0293	263251	CRTH258A2303: Brolucizumab 6 mg vs aflibercept 2 mg in nAMD (TALON)	Number Agreed	4	5	Date Agreed	17/10/2020	4	07/05/2021	4	Recruitment Finished